Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia | Zendy

Nobuko Hijiya | Zendy; Alexey Maschan | Zendy; Carmelo Rizzari | Zendy; Hiroyuki Shimada | Zendy; Carlo Dufour | Zendy; Hiroaki Goto | Zendy; Hyoung Jin Kang | Zendy; Terri Guinipero | Zendy; Zeynep Karakaş | Zendy; Francisco Bautista | Zendy; Stéphane Ducassou | Zendy; Keon Hee Yoo | Zendy; C. Michel Zwaan | Zendy; Frédéric Millot | Zendy; Paola Aimone | Zendy; Alex Allepuz | Zendy; Sara Quenet | Zendy; Florence HourcadePotelleret | Zendy; Sabine Hertle | Zendy; Darintr Sosothikul | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome–positive chronic myeloid leukemia

Author(s) -

Nobuko Hijiya,

Alexey Maschan,

Carmelo Rizzari,

Hiroyuki Shimada,

Carlo Dufour,

Hiroaki Goto,

Hyoung Jin Kang,

Terri Guinipero,

Zeynep Karakaş,

Francisco Bautista,

Stéphane Ducassou,

Keon Hee Yoo,

C. Michel Zwaan,

Frédéric Millot,

Paola Aimone,

Alex Allepuz,

Sara Quenet,

Florence HourcadePotelleret,

Sabine Hertle,

Darintr Sosothikul

Publication year - 2019

Publication title -

blood

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 5.515

H-Index - 465

eISSN - 1528-0020

pISSN - 0006-4971

DOI - 10.1182/blood.2019000069

Subject(s) - nilotinib , medicine , dasatinib , imatinib , myeloid leukemia , philadelphia chromosome , clinical endpoint , imatinib mesylate , gastroenterology , adverse effect , oncology , clinical trial , chromosomal translocation , biochemistry , chemistry , gene

Key Points Nilotinib demonstrated efficacy and a manageable safety profile in pediatric patients with newly diagnosed and pretreated Ph+ CML-CP.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research